Skip to main content

Table 2 Restricted or prohibited immunomodulatory or antifibrotic therapies taken at baseline, during treatment with trial drug and/or following discontinuation of trial drug over 52 weeks by customized drug grouping or preferred name

From: Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

  Nintedanib (n = 332) Placebo (n = 331)
≥ 1 restricted or prohibited therapy 53 (16.0) 91 (27.5)
Glucocorticoidsa 44 (13.3) 72 (21.8)
Mycophenolate mofetil 9 (2.7) 9 (2.7)
Azathioprine 4 (1.2) 6 (1.8)
Tacrolimus 4 (1.2) 5 (1.5)
Ciclosporin 1 (0.3) 6 (1.8)
Rituximab 3 (0.9) 2 (0.6)
Cyclophosphamide 0 (0.0) 3 (0.9)
Nintedaniba 0 (0.0) 3 (0.9)
Pirfenidonea 2 (0.6) 1 (0.3)
  1. Data are n (%) of subjects who took ≥ 1 such therapy at baseline, during treatment with trial drug, and/or following discontinuation of trial drug (up to week 52) for any duration. Glucocorticoids were only counted as restricted therapies if used at high dose (> 20 mg/day prednisone or equivalent) and if the route of administration was oral, intravenous, intravenous bolus, intravenous drip, or intramuscular. Other therapies are displayed regardless of dose or route of administration
  2. aBased on customized drug grouping; for other therapies, preferred names are shown